News

NIOX Group plc is an LSE AIM listed medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. 

The company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence. 

Launch of Tender offer 

On 29 September 2026, the Company announced the proposed return of up to £12.5 million by way of a purchase of up to 15,625,000 Ordinary Shares at 80 pence per share pursuant to a Tender Offer. 

The Perivan shareholder communications team was delighted to work with Singer Capital Markets who acted as Nominated Adviser and Broker and Shoosmiths who acted as Legal adviser on the production of the documentation which was successfully completed and posted to qualifying shareholders on 29 September 2026. 

Perivan specialises in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and is a market leader in the production of documentation relating to corporate finance transactions.